Literature DB >> 20625469

Exploring Potential Binding Modes of Small Drug-like Molecules to the Polo-Box Domain of Human Polo-like Kinase 1.

Chenzhong Liao1, Jung-Eun Park, Jeong Kyu Bang, Marc C Nicklaus, Kyung S Lee.   

Abstract

Purpurogallin (PPG) and Poloxin have been reported as inhibitors of the polo-box domain (PBD) of human polo-like kinase 1 (Plk1). However, our experimental results demonstrated that PPG, but not Poloxin, binds to the phospho-binding pocket of the PBD, suggesting that their modes of PBD inhibition are distinct. Induced fit docking (IFD) analyses led us to propose that PPG fills the SpT pocket via pi-pi stacking and hydrogen bonding interactions, thus providing a rationale for designing novel PBD inhibitors. In contrast, Poloxin may fill a different site present near the SpT pocket by forming a covalent bond with a nucleophilic Cys residue.

Entities:  

Year:  2010        PMID: 20625469      PMCID: PMC2898210          DOI: 10.1021/ml100020e

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  18 in total

Review 1.  Polo-like kinases: conservation and divergence in their functions and regulation.

Authors:  Vincent Archambault; David M Glover
Journal:  Nat Rev Mol Cell Biol       Date:  2009-04       Impact factor: 94.444

2.  The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1.

Authors:  Péter Lénárt; Mark Petronczki; Martin Steegmaier; Barbara Di Fiore; Jesse J Lipp; Matthias Hoffmann; Wolfgang J Rettig; Norbert Kraut; Jan-Michael Peters
Journal:  Curr Biol       Date:  2007-02-08       Impact factor: 10.834

3.  Self-regulated Plk1 recruitment to kinetochores by the Plk1-PBIP1 interaction is critical for proper chromosome segregation.

Authors:  Young H Kang; Jung-Eun Park; Li-Rong Yu; Nak-Kyun Soung; Sang-Moon Yun; Jeong K Bang; Yeon-Sun Seong; Hongtao Yu; Susan Garfield; Timothy D Veenstra; Kyung S Lee
Journal:  Mol Cell       Date:  2006-11-03       Impact factor: 17.970

Review 4.  Chemical modification of proteins at cysteine: opportunities in chemistry and biology.

Authors:  Justin M Chalker; Gonçalo J L Bernardes; Yuya A Lin; Benjamin G Davis
Journal:  Chem Asian J       Date:  2009-05-04

5.  The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex.

Authors:  Kin-Yip Cheng; Edward D Lowe; John Sinclair; Erich A Nigg; Louise N Johnson
Journal:  EMBO J       Date:  2003-11-03       Impact factor: 11.598

6.  Comparison of nine programs predicting pK(a) values of pharmaceutical substances.

Authors:  Chenzhong Liao; Marc C Nicklaus
Journal:  J Chem Inf Model       Date:  2009-12       Impact factor: 4.956

7.  Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1.

Authors:  Sang-Moon Yun; Tinoush Moulaei; Dan Lim; Jeong K Bang; Jung-Eun Park; Shilpa R Shenoy; Fa Liu; Young H Kang; Chenzhong Liao; Nak-Kyun Soung; Sunhee Lee; Do-Young Yoon; Yoongho Lim; Dong-Hee Lee; Akira Otaka; Ettore Appella; James B McMahon; Marc C Nicklaus; Terrence R Burke; Michael B Yaffe; Alexander Wlodawer; Kyung S Lee
Journal:  Nat Struct Mol Biol       Date:  2009-07-13       Impact factor: 15.369

8.  Mechanisms of mammalian polo-like kinase 1 (Plk1) localization: self- versus non-self-priming.

Authors:  Kyung S Lee; Jung-Eun Park; Young H Kang; Wendy Zimmerman; Nak-Kyun Soung; Yeon-Sun Seong; Sahng-June Kwak; Raymond L Erikson
Journal:  Cell Cycle       Date:  2007-10-16       Impact factor: 4.534

9.  Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.

Authors:  Wolfgang Reindl; Juping Yuan; Andrea Krämer; Klaus Strebhardt; Thorsten Berg
Journal:  Chem Biol       Date:  2008-05

10.  The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain.

Authors:  Andrew E H Elia; Peter Rellos; Lesley F Haire; Jerry W Chao; Frank J Ivins; Katja Hoepker; Duaa Mohammad; Lewis C Cantley; Stephen J Smerdon; Michael B Yaffe
Journal:  Cell       Date:  2003-10-03       Impact factor: 41.582

View more
  25 in total

Review 1.  Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy.

Authors:  Kyung S Lee; Terrence R Burke; Jung-Eun Park; Jeong K Bang; Eunhye Lee
Journal:  Trends Pharmacol Sci       Date:  2015-10-17       Impact factor: 14.819

2.  Novel Toxoplasma gondii inhibitor chemotypes.

Authors:  A G Sanford; T T Schulze; L P Potluri; R M Hemsley; J J Larson; A K Judge; S J Zach; X Wang; S A Charman; J L Vennerstrom; P H Davis
Journal:  Parasitol Int       Date:  2018-01-04       Impact factor: 2.230

Review 3.  Understanding the Polo Kinase machine.

Authors:  V Archambault; G Lépine; D Kachaner
Journal:  Oncogene       Date:  2015-01-26       Impact factor: 9.867

4.  Selective blockade of cancer cell proliferation and anchorage-independent growth by Plk1 activity-dependent suicidal inhibition of its polo-box domain.

Authors:  Jung-Eun Park; Tae-Sung Kim; Bo Yeon Kim; Kyung S Lee
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

5.  Identification of Polo-like kinase 1 interaction inhibitors using a novel cell-based assay.

Authors:  Karine Normandin; Jean-François Lavallée; Marie Futter; Alexandre Beautrait; Jean Duchaine; Sébastien Guiral; Anne Marinier; Vincent Archambault
Journal:  Sci Rep       Date:  2016-11-22       Impact factor: 4.379

Review 6.  Software and resources for computational medicinal chemistry.

Authors:  Chenzhong Liao; Markus Sitzmann; Angelo Pugliese; Marc C Nicklaus
Journal:  Future Med Chem       Date:  2011-06       Impact factor: 3.808

Review 7.  Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity.

Authors:  Ravichandran N Murugan; Jung-Eun Park; Eun-Hee Kim; Song Yub Shin; Chaejoon Cheong; Kyung S Lee; Jeong Kyu Bang
Journal:  Mol Cells       Date:  2011-07-29       Impact factor: 5.034

8.  Development of cyclic peptomer inhibitors targeting the polo-box domain of polo-like kinase 1.

Authors:  Ravichandran N Murugan; Jung-Eun Park; Dan Lim; Mija Ahn; Chaejoon Cheong; Taeho Kwon; Ky-Youb Nam; Sun Ho Choi; Bo Yeon Kim; Do-Young Yoon; Michael B Yaffe; Dae-Yeul Yu; Kyung S Lee; Jeong Kyu Bang
Journal:  Bioorg Med Chem       Date:  2013-02-27       Impact factor: 3.641

9.  Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype.

Authors:  Campbell McInnes; Kara Estes; Merissa Baxter; Zhengguan Yang; Doaa Boshra Farag; Paul Johnston; John S Lazo; Jianjun Wang; Michael D Wyatt
Journal:  Mol Cancer Ther       Date:  2012-07-30       Impact factor: 6.261

10.  Computational analysis of phosphopeptide binding to the polo-box domain of the mitotic kinase PLK1 using molecular dynamics simulation.

Authors:  David J Huggins; Grahame J McKenzie; Daniel D Robinson; Ana J Narváez; Bryn Hardwick; Meredith Roberts-Thomson; Ashok R Venkitaraman; Guy H Grant; Mike C Payne
Journal:  PLoS Comput Biol       Date:  2010-08-12       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.